Experienced in Virilizing Ovarian Tumor

Dr. Rodolfo E. Bordoni

Hematology Oncology
1100 Johnson Ferry Rd Ste 600, 
Atlanta, GA 
Clinical Trials:Currently Recruiting for 3 Trials
Experienced in Virilizing Ovarian Tumor
1100 Johnson Ferry Rd Ste 600, 
Atlanta, GA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Rodolfo Bordoni is a Hematologist Oncology provider in Atlanta, Georgia. Dr. Bordoni is rated as an Experienced provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Hodgkin Lymphoma, and Tissue Biopsy.

His clinical research consists of co-authoring 14 peer reviewed articles and participating in 27 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Licenses
Internal Medicine in GA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

1100 Johnson Ferry Rd Ste 600, Atlanta, GA 30342

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

26 Clinical Trials

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Carboplatin, Cisplatin, Gemcitabine Hydrochloride, Paclitaxel, Pembrolizumab, Pemetrexed Disodium
Study Phase: Phase 3
Phase III Trial of Stereotactic Radiosurgery (SRS) Versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for Brain Metastases From Small Cell Lung Cancer
Phase III Trial of Stereotactic Radiosurgery (SRS) Versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for Brain Metastases From Small Cell Lung Cancer
Enrollment Status: Recruiting
Publish Date: September 11, 2025
Intervention Type: Procedure, Other, Radiation, Drug
Study Drug: Memantine Hydrochloride
Study Phase: Phase 3
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
Enrollment Status: Recruiting
Publish Date: May 25, 2025
Intervention Type: Procedure, Radiation
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: October 06, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Previously Treated Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Topotecan Chemotherapy
Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Previously Treated Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Topotecan Chemotherapy
Enrollment Status: Completed
Publish Date: September 25, 2025
Intervention Type: Drug
Study Drugs: Trilaciclib, Topotecan
Study Phase: Phase 1/Phase 2
Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (SCLC)
Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (SCLC)
Enrollment Status: Completed
Publish Date: September 25, 2025
Intervention Type: Drug
Study Drugs: Trilaciclib, Carboplatin, Etoposide, Atezolizumab
Study Phase: Phase 2
A Phase Ib Trial of Neoadjuvant AMG 232 (KRT-232) Concurrent With Preoperative Radiotherapy in Wild-Type P53 Soft Tissue Sarcoma (STS)
A Phase Ib Trial of Neoadjuvant AMG 232 (KRT-232) Concurrent With Preoperative Radiotherapy in Wild-Type P53 Soft Tissue Sarcoma (STS)
Enrollment Status: Completed
Publish Date: September 23, 2025
Intervention Type: Drug, Radiation, Procedure
Study Drug: MDM2 Inhibitor KRT-232
Study Phase: Phase 1
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Carboplatin, Pembrolizumab, Pemetrexed
Study Phase: Phase 3
A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol
A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol
Enrollment Status: Active_not_recruiting
Publish Date: August 13, 2025
Intervention Type: Drug
Study Drugs: Alectinib, Brigatinib, Carboplatin, Ceritinib, Cisplatin, Crizotinib, Ensartinib, Lorlatinib, Pemetrexed
Study Phase: Phase 2
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: May 21, 2025
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
PRESERVE 1: A Phase 3 Randomized, Double-blind Trial of Trilaciclib Versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer
PRESERVE 1: A Phase 3 Randomized, Double-blind Trial of Trilaciclib Versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer
Enrollment Status: Terminated
Publish Date: November 26, 2024
Intervention Type: Drug
Study Drug: Trilaciclib
Study Phase: Phase 3
A Phase 1, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors
A Phase 1, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: August 09, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients With Significant Comorbidities Ineligible for Standard Chemotherapy
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients With Significant Comorbidities Ineligible for Standard Chemotherapy
Enrollment Status: Completed
Publish Date: June 11, 2024
Intervention Type: Drug
Study Drugs: Brentuximab, Bendamustine, Dacarbazine, Nivolumab
Study Phase: Phase 2
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Enrollment Status: Completed
Publish Date: May 03, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies
A Phase 1 Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies
Enrollment Status: Completed
Publish Date: March 28, 2024
Intervention Type: Drug
Study Drugs: CDX-1140, CDX-301, Pembrolizumab, Gemcitabine, Nab-Paclitaxel
Study Phase: Phase 1
A Phase I, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-0184 Administered Once Weekly for 4 Weeks to Patients With Advanced Solid Tumors
A Phase I, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-0184 Administered Once Weekly for 4 Weeks to Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: November 14, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies
A Phase 1 Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies
Enrollment Status: Completed
Publish Date: June 18, 2023
Intervention Type: Drug
Study Drug: CDX-527
Study Phase: Phase 1
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Biological, Other
Study Drugs: Durvalumab, Tremelimumab
Study Phase: Phase 2
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Enrollment Status: Completed
Publish Date: June 01, 2023
Intervention Type: Biological, Drug, Other
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
Enrollment Status: Completed
Publish Date: October 06, 2022
Intervention Type: Drug
Study Drugs: Avapritinib, Regorafenib
Study Phase: Phase 3
A Phase 1b (Open-Label)/Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma
A Phase 1b (Open-Label)/Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma
Enrollment Status: Completed
Publish Date: May 09, 2022
Intervention Type: Drug
Study Drugs: Olaratumab, Gemcitabine, Docetaxel
Study Phase: Phase 1/Phase 2
First-in-human, Dose-escalating Safety Study of Tissue Factor Specific Antibody Drug Conjugate Tisotumab Vedotin (HuMax® TF ADC) in Patients With Locally Advanced and/or Metastatic Solid Tumors Known to Express Tissue Factor
First-in-human, Dose-escalating Safety Study of Tissue Factor Specific Antibody Drug Conjugate Tisotumab Vedotin (HuMax® TF ADC) in Patients With Locally Advanced and/or Metastatic Solid Tumors Known to Express Tissue Factor
Enrollment Status: Completed
Publish Date: December 29, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: June 23, 2021
Intervention Type: Other, Drug
Study Drug: Talazoparib
Study Phase: Phase 2
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: May 27, 2021
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Palbociclib
Study Phase: Phase 2/Phase 3
View 23 Less Clinical Trials

14 Total Publications

Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy.
Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy.
Journal: Blood
Published: January 24, 2023
Similar Doctors
Advanced in Virilizing Ovarian Tumor
Dr. Gena H. Volas-Redd
Hematology Oncology | Hematology | Oncology
Advanced in Virilizing Ovarian Tumor
Dr. Gena H. Volas-Redd
Hematology Oncology | Hematology | Oncology

Nsh Cancer Institute Professional Services G LLC

790 Church St Ne, Suite 335, 
Marietta, GA 
 (12.3 miles away)
770-590-8311
Languages Spoken:
English, Greek, Spanish
See accepted insurances
Accepting New Patients

Gena Volas-Redd is a Hematologist Oncology specialist and a Hematologist in Marietta, Georgia. Dr. Volas-Redd is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Astrocytoma, and Gliosarcoma. Dr. Volas-Redd is currently accepting new patients.

Advanced in Virilizing Ovarian Tumor
Dr. Navneet K. Dhillon
Hematology Oncology | Oncology
Advanced in Virilizing Ovarian Tumor
Dr. Navneet K. Dhillon
Hematology Oncology | Oncology

Nsh Cancer Institute Professional Services G LLC

1521 Hickory Flat Hwy, Suite 100, 
Canton, GA 
 (20.7 miles away)
770-479-1870
Languages Spoken:
English, Hindi, Punjabi, Urdu
See accepted insurances
Accepting New Patients

Navneet Dhillon is a Hematologist Oncology specialist and an Oncologist in Canton, Georgia. Dr. Dhillon is rated as an Advanced provider by MediFind in the treatment of Virilizing Ovarian Tumor. Her top areas of expertise are Childhood Iron Deficiency Anemia, Ovarian Carcinosarcoma, Virilizing Ovarian Tumor, and Endometrial Cancer. Dr. Dhillon is currently accepting new patients.

Advanced in Virilizing Ovarian Tumor
Dr. Melvin R. Moore
Hematology Oncology | Oncology
Advanced in Virilizing Ovarian Tumor
Dr. Melvin R. Moore
Hematology Oncology | Oncology
2712 Lawrenceville Hwy, 
Decatur, GA 
 (7.7 miles away)
770-496-5555
Languages Spoken:
English
See accepted insurances

Melvin Moore is a Hematologist Oncology specialist and an Oncologist in Decatur, Georgia. Dr. Moore is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Pleuropulmonary Blastoma, and Laryngeal Cancer.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bordoni's expertise for a condition
ConditionClose
    View All 10 Advanced Conditions
    View All 59 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile